Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kemaiping Granules in Diabetic Kidney Disease (Qi-Yin Deficiency with Blood Stasis) Phase II Trial
CTR20254571Phase 2Active
- Sponsor
- Houcheng Pharma
- Start
- Dec 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis comparing Kemaiping Granules with Placebo (2 arms). Primary endpoints: Change in eGFR from baseline at week 24, Proportion of subjects with ≥30% reduction in 24-hour urinary protein excretion at week 24 and 6 more. Started Dec 2025; status: active.
02
Drugs
Kemaiping Granules
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on CTR20254571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254571.